Medicines Discovery Catapult Translational Imaging

Translational Imaging for Accelerated Drug Development Delivering unrivalled translational imaging capabilities, using our portfolio of imaging platforms, infrastructure and expertise

Monitoring, assessing, and characterising novel therapeutics in pre-clinical models plays an essential part in drug development.

All drugs have an optimum concentration range in which maximum benefit is achieved. Translational imaging can help scientists optimise the selective delivery of a therapeutic concentration of a drug to its target tissue.

As an expert in medicines discovery, Medicines Discovery Catapult (MDC) has established a portfolio of advanced imaging platforms, infrastructure and expertise, to support the assessment of novel therapeutics in pre-clinical models, to accelerate drug development and achieve maximum therapeutic benefit.

Who is MDC? We are an independent, not-for-profit organisation and part of the Catapult Network established by Innovate UK. Our vision is to reshape drug discovery for patient benefit by transforming great UK science into better treatments through partnership. We support drug discovery innovators by making world-class expertise, facilities, complex technologies

and advanced analytics accessible.

We connect the life sciences ecosystem, driving a global focus on barriers to innovation in areas of unmet patient and technological need. We enable successful medicines discovery by industrialising new technologies to drive the adoption of new scientific tools and techniques.

As an SME, working with MDC allows us access to scientific know-how and in vivo imaging techniques that would be impossible through any other route. The closeness, timeliness and flexibility of the collaboration significantly accelerates our ability to develop product. MDC perform an absolutely vital role in supporting us getting our novel treatments to clinical trials.

Gareth Wakefield Chief Technology Officer, Xerion Healthcare

The ability to perform non-invasive imaging to assess and study novel therapeutics requires significant investment in infrastructure as well as highly experienced specialists, and access to relevant disease models. At MDC, we provide access to all three.

Non-invasive Imaging Modalities We focus on non-invasive imaging modalities to study biodistribution of novel therapeutics, as well as its pharmacokinetics and pharmacodynamics.

These non-invasive techniques include:

Positron Emission Tomography

Gamma Counting Biodistribution Analysis

Radiochemistry Capabilities Including Cyclotron

Computed Tomography

High-Frequency Ultrasound

Bioluminescence /NIR Imaging

Radiotherapy System

Focused Ultrasound

Mass Spectrometry Imaging

Molecular Pathology

Spatial Transcriptomic Capability

Complex Microscopy (supra-resolution/ confocal)

How We Can Help Our multi-disciplinary translational imaging team are experts in their field, validating therapeutic targets and platforms for use in the clinical setting.

From radiochemistry expertise to industrial translational imaging acquisition, alongside complex in vivo modelling expertise.

We offer unrivalled know-how, and can support you with:

Guidance on using in vivo imaging in drug discovery and development programmes

Novel technologies and probes, to further develop translational imaging methods

Multiple disease areas, with a wealth of diverse models available

Novel methods for targeted drug delivery

Total Body (clinical) PET – MDC is the management lead for the very first national Total Body (clinical) PET platform

How to Contact Us Medicines Discovery Catapult Alderley Park, Mereside, Macclesfield, SK10 4ZF md.catapult.org.uk info@md.catapult.org.uk @MedDiscCat